Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
111.97M | 144.63M | 210.26M | 214.00M | 200.50M | 222.19M | Gross Profit |
47.71M | 76.55M | 58.18M | 46.02M | 43.39M | 65.93M | EBIT |
-13.98M | -8.18M | 8.49M | 875.00K | 831.00K | 26.46M | EBITDA |
-10.27M | -4.92M | 8.51M | 7.44M | 2.57M | 23.51M | Net Income Common Stockholders |
-18.48M | -15.99M | -5.06M | 333.00K | -5.37M | 6.06M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
11.72M | 24.77M | 7.03M | 13.14M | 7.35M | 7.15M | Total Assets |
129.41M | 146.90M | 190.06M | 215.76M | 199.59M | 190.82M | Total Debt |
8.22M | 19.85M | 25.45M | 29.38M | 20.93M | 24.67M | Net Debt |
-3.50M | -4.92M | 18.42M | 16.24M | 13.57M | 17.52M | Total Liabilities |
41.26M | 57.26M | 80.61M | 94.95M | 84.96M | 100.59M | Stockholders Equity |
88.15M | 89.64M | 109.45M | 120.81M | 114.62M | 90.23M |
Cash Flow | Free Cash Flow | ||||
5.00M | 9.64M | 4.70M | 16.32M | 168.00K | 17.52M | Operating Cash Flow |
7.71M | 12.34M | 6.55M | 18.57M | 2.69M | 19.33M | Investing Cash Flow |
14.66M | 16.29M | -1.85M | -2.25M | -31.80M | -8.14M | Financing Cash Flow |
-20.73M | -10.90M | -10.91M | -10.59M | 29.42M | -14.51M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
77 Outperform | $29.13B | 26.25 | 30.87% | 3.18% | 6.00% | 4.02% | |
73 Outperform | €246.99M | 39.92 | 3.33% | 1.98% | 3.37% | -25.24% | |
62 Neutral | $6.88B | 11.32 | 2.95% | 3.87% | 2.70% | -24.57% | |
47 Neutral | AU$38.15M | ― | -14.68% | 8.87% | -44.48% | -419.84% | |
47 Neutral | $4.12B | 23.42 | -1.04% | ― | -65.07% | -102.37% |
McPherson’s Limited has announced a strategic shift in its operating model by transitioning from direct-to-store orders to utilizing a third-party logistics provider and pharmacy wholesalers. This change is marked by a new three-year agreement with Symbion Pty Ltd, starting June 2025, which will handle an estimated $10-$15 million in annual revenue previously managed under the direct-to-store model. This move is expected to streamline operations and potentially enhance McPherson’s market positioning by leveraging Symbion’s distribution capabilities.
McPherson’s Limited has announced a strategic shift in its operating model by exiting its warehousing and direct-to-store orders, opting instead to partner with third-party logistics and pharmacy wholesalers. This transition includes a new three-year agreement with Sigma Company Limited, which will handle orders previously managed directly by McPherson’s, impacting annual revenue of approximately $50 – $55 million. This move is expected to streamline operations and potentially enhance the company’s market positioning by leveraging Sigma’s distribution capabilities.